September 29, 2017 / 11:12 AM / 3 months ago

BRIEF-Avexis to initiate pivotal trial of AVXS-101 in SMA type 1

Sept 29 (Reuters) - Avexis Inc

* Avexis announces plan to initiate pivotal trial of AVXS-101 in SMA type 1 using product from new GMP commercial process

* Says ‍company plans to initiate trial trial of AVXS-101 immediately​

* Says ‍an update on the AVXS-101 program will be provided in Q4 of 2017​

* Avexis Inc - co ‍and FDA are continuing discussions on key topics, including dosing, for intrathecal administration of AVXS-101 for planned clinical trial

* Avexis Inc - ‍FDA may initiate pivotal trial of AVXS-101 for patients with SMA type 1 using IV formulation produced by GMP commercial manufacturing process​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below